The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies. Over the past five years, deal-making has occurred at a rapid pace, and regenerative medicine-focused biotech companies have drawn top dollar in both partnering and mergers and acquisitions.

This Datamonitor Healthcare report contains a Strategy module.